Associated Papers
Dideoxy Sequencing Enhances Detection of KIT Mutations in Gastrointestinal Stromal Tumors Initially Evaluated by Next-Generation Sequencing Hotspot Panels.
Robinson L et al.
The Journal of Molecular Diagnostics : Jmd, 2026
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report.
Ishfaq H et al.
Journal of Gastrointestinal Cancer, 2025
Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.
Hida T et al.
Cancer Medicine, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J et al.
Cell Reports. Medicine, 2024
Preferential MGMT hypermethylation in SDH-deficient wild-type GIST.
Giger OT et al.
Journal of Clinical Pathology, 2023
When Mast Cells Run Amok: A Comprehensive Review and Case Study on Severe Neonatal Diffuse Cutaneous Mastocytosis.
Olteanu EG et al.
Genes, 2023
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A et al.
Diagnostics (basel, Switzerland), 2023
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
Kage H et al.
Cancer Science, 2023
Small Gastric Stromal Tumors: An Underestimated Risk.
Guo J et al.
Cancers, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data.
Nardi V et al.
Archives of Pathology & Laboratory Medicine, 2022
Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.
Ko TK et al.
Frontiers in Oncology, 2022
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors.
Palomba G et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ecp), 2021
Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors.
Feng Y et al.
Frontiers in Cell and Developmental Biology, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Bombac A et al.
International Journal of Oncology, 2020
Mutation of the KIT Gene, excluding Exon 11, in Gastrointestinal Stromal Tumors.
Liu QY et al.
Biomedical and Environmental Sciences : Bes, 2020
Justification of direct Sanger sequencing application for detection of KIT and PDGFRα gene mutations in formalin-fixed, paraffin-embedded samples from gastrointestinal stromal tumours.
Kiwerska K et al.
Journal of Clinical Pathology, 2020
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S et al.
Frontiers in Oncology, 2020
Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST.
Astolfi A et al.
Frontiers in Oncology, 2020
Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.
Jiang L et al.
American Journal of Cancer Research, 2020
Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors.
Ohshima K et al.
Cancer Science, 2019
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S et al.
Cancer Cell International, 2019
Results of the UK NEQAS for Molecular Genetics reference sample analysis.
Richman SD et al.
Journal of Clinical Pathology, 2018
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Detailed overview on the mutations detected by and the sensitivity of the GeneReader NGS sequencing platform.
Lüsebrink J et al.
Data in Brief, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V et al.
Plos One, 2018
Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece.
Mavroeidis L et al.
Esmo Open, 2018
Microscopic gastrointestinal stromal tumours: a clinical and molecular study of 13 cases.
Anderson W et al.
Histopathology, 2017
Synchronous GISTs associated with multiple sporadic tumors: a case report.
Comandini D et al.
Drugs in Context, 2017
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015